On 2018-12-28, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab), an immunotherapy developed by Merck Sharp Dohme. This specific approval, identified as BLA 125514 S-37, was based on new efficacy data, indicating an expansion of the drug's approved uses for a new patient population or indication.
What this means
This supplemental approval for Keytruda (pembrolizumab) represents a significant development for patients and clinicians. As an efficacy-based approval, it confirms that Keytruda has demonstrated a statistically significant and clinically meaningful benefit in a new therapeutic context. While the specific details of the new indication or patient population are not provided in the source data, this type of approval typically allows the drug to be prescribed for an expanded set of conditions or in different stages of an existing condition. For healthcare providers, this means an additional, FDA-validated treatment option is now available for patients who meet the criteria for this new indication, potentially improving outcomes for those who previously had limited choices. The FDA's rigorous review process ensures that such approvals are backed by robust clinical evidence of effectiveness.
Source
The information regarding this supplemental approval was directly sourced from the U.S. Food and Drug Administration (FDA). The approval for Keytruda (pembrolizumab), specifically supplemental application BLA 125514 S-37, was officially granted on 2018-12-28. Further details can be verified through the FDA's accessdata.fda.gov portal.